How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and more.
External link. We are not responsible for the content.
Read more ↗More From PsyMed Ventures
The Future of Whole Brain Emulation
Whole brain emulation without the sci-fi, by PsyMed’s Danny Carbonero
Inside Philanthropy’s Role in Mental & Brain Health
Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it
Rick Perry on paving the way for Ibogaine in America
Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it
Latest News
Meet Yopo, Ayahuasca's Grandfather: the Sacred Plant No One's Heard Of.
Yopo, the oldest of them all, the grandfather of the entire lineage, the medicine with the longest unbroken ceremoni...
2026 First Quarter — Legislative Wrap Up
2026 will likely be an important year for psychedelic policy reform, with over a dozen states considering legislation...
Drop the Dogma, Celebrate Easter with Psychedelics Instead
Comedy specials, Robin Carhart-Harris, brain-made DMT, and land-based healing. [...] Read More... The post Drop the D...
What If I Remember It Wrong?
This week’s Sunday Insider: What if the memories you built your identity around aren’t as stable as you think.
The Uncanny Normality That Follows Mystical Experiences
After a profound mystical experience that feels life-changing and deeply meaningful, returning to everyday life can f...
Queensland's Illicit Drug Enforcement and Diversion Framework: A Clinical Assessment
The Queensland Government is dismantling its expanded drug diversion program — a decision that peak medical, nursing,...